Drugs Made In America Acquisition II Rights Exp 16 Sep 2030
DMIIR0.116USD
0.0000.00%
종가 01/27, 16:00（ET）시세는 15분 지연됩니다
0.00시가총액
--P/E TTM
자세한 내용은 Drugs Made In America Acquisition II Rights Exp 16 Sep 2030 회사
Drugs Made In America Acquisition II Corp. is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses. The Company intends to search for business combination targets in the pharmaceutical industry. The Company is neither engaged in any operations nor generated any revenues.
Drugs Made In America Acquisition II Rights Exp 16 Sep 2030 정보
종목 코드 DMIIR
회사 이름Drugs Made In America Acquisition II Corp
상장일Sep 25, 2025
CEOStockwell (Lynn)
직원 수- -
유형Right
회계 연도 종료- -
주소1 East Broward Boulevard
도시FT LAUDERDALE
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호33301
전화19548703099
웹사이트
종목 코드 DMIIR
상장일Sep 25, 2025
CEOStockwell (Lynn)
Drugs Made In America Acquisition II Rights Exp 16 Sep 2030의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Ms. Lynn Stockwell
Ms. Lynn Stockwell
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Mr. Glenn Worman
Mr. Glenn Worman
Chief Financial Officer, Principal Financial and Accounting Officer
Chief Financial Officer, Principal Financial and Accounting Officer
--
--
Dr. Catherine Do
Dr. Catherine Do
Independent Director
Independent Director
--
--
Dr. G. Sridhar Prasad
Dr. G. Sridhar Prasad
Independent Director
Independent Director
--
--
Mr. Myron W. Shulgan
Mr. Myron W. Shulgan
Independent Director
Independent Director
--
--
Mr. Saleem Elmasri, CPA
Mr. Saleem Elmasri, CPA
Chief Financial Officer, Principal Financial and Accounting Officer
Chief Financial Officer, Principal Financial and Accounting Officer
--
--
Ms. Lynn Stockwell
Ms. Lynn Stockwell
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Mr. Glenn Worman
Mr. Glenn Worman
Chief Financial Officer, Principal Financial and Accounting Officer
Chief Financial Officer, Principal Financial and Accounting Officer
--
--
Dr. Catherine Do
Dr. Catherine Do
Independent Director
Independent Director
--
--
Dr. G. Sridhar Prasad
Dr. G. Sridhar Prasad
Independent Director
Independent Director
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Ms. Lynn Stockwell
Ms. Lynn Stockwell
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Mr. Glenn Worman
Mr. Glenn Worman
Chief Financial Officer, Principal Financial and Accounting Officer
Chief Financial Officer, Principal Financial and Accounting Officer
--
--
Dr. Catherine Do
Dr. Catherine Do
Independent Director
Independent Director
--
--
Dr. G. Sridhar Prasad
Dr. G. Sridhar Prasad
Independent Director
Independent Director
--
--
Mr. Myron W. Shulgan
Mr. Myron W. Shulgan
Independent Director
Independent Director
--
--
Mr. Saleem Elmasri, CPA
Mr. Saleem Elmasri, CPA
Chief Financial Officer, Principal Financial and Accounting Officer
Chief Financial Officer, Principal Financial and Accounting Officer
--
--
수익 분석
기업이 아직 관련 데이터를 공개하지 않았습니다.
기업이 아직 관련 데이터를 공개하지 않았습니다.
사업별
지역별
기업이 아직 관련 데이터를 공개하지 않았습니다.
주식 보유 통계
주주
주주 유형
주주
주주
비율
기타
100.00%
주주
주주
비율
기타
100.00%
주주 유형
주주
비율
기타
100.00%
기관 주식 보유
기업이 아직 관련 데이터를 공개하지 않았습니다.
보고 기간
기관 수
보유 주식
비율
변동
데이터 없음
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
데이터 없음
관련 ETF
이름
비율
데이터 없음
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
배당락일
유형
비율
데이터 없음
날짜
배당락일
유형
비율
데이터 없음
